ClinicalTrials.gg
WithdrawnNCT05323617Updated Sep 29, 2023

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

A Phase 2 interventional study of Romiplostim and Antithymocyte Globulin in Severe Aplastic Anemia (SAA), sponsored by Amgen. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Operational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing romiplostim in Anemia, Aplastic — 6 open to participants now, 6 under way, 1 of them phase 3. romiplostim · Anemia, Aplastic.

Enrollment
12th of 15
0 · median 35
Started
2023
the only one that year
Phase 2
8 of 15
3 open now
Registered
6th of 15
by date
Lead sponsor
1 of 15
Amgen

Among the 15 studies testing romiplostim in Anemia, Aplastic, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 8 in phase 2, and was the 6th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

6 of the 15 studies testing romiplostim in Anemia, Aplastic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing romiplostim in Anemia, Aplastic, or all of them as a file.
02

Study summary

Romiplostim has been used in clinical trials for the treatment of severe and very severe aplastic anemia (SAA/vSAA) in Asian participants who are either previously untreated with immunosuppressive therapy (IST) or refractory to IST. This study will evaluate the efficacy of romiplostim in the treatment of participants with SAA/vSAA.

The primary objectives of this study are to:

Arm 1: Evaluate the efficacy of romiplostim and IST in adult SAA/vSAA participants who are previously untreated with IST (1L)

Arm 2: Evaluate the efficacy of romiplostim treatment in adult SAA/vSAA participants who are refractory to IST (2L+)

03

Conditions studied

  • Severe Aplastic Anemia (SAA)

Browse trials for

Keywords

  • Severe Aplastic Anemia
  • SAA
  • Very Severe Aplastic Anemia
  • vSAA
  • Romiplostim
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at time of enrollment
  • Diagnosis of SAA/vSAA confirmed by blood, bone marrow, and cytogenetic studies
  • An (ECOG) performance status score of 0 to 1 at screening
  • Arm 1 only: participant requires initial treatment for SAA/vSAA, no matched related donor is available for allogenic hematopoietic cell transplantation (HCT) and will begin IST with antithymocyte globulin and CsA
  • Arm 2 only: to at least one course of therapy including horse or rabbit ATG; or ineligible for ATG treatment and refractory to CsA

Exclusion criteria

Exclusion Criteria:

  • Diagnosed as having congenital aplastic anemia (AA) (Fanconi anemia, congenital dyskeratosis, etc)
  • History of other within the past 5 years, with exceptions.
  • Aplastic anemia with hemolytic paroxysmal nocturnal hemoglobinuria (PNH) (hemolytic predominant is defined as lactate dehydrogenase (LDH) > 1.5 x the upper limit of site normal
  • Arm 1 only: Previously treated with ATG, CsA, or Alemtuzumab
  • Previously treated with PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin protein (TPO), romiplostim and other TPO-receptor agonist (eltrombopag, etc)
  • Patients who are eligible for allogenic HCT and have an available matched related donor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm 1: Previously Untreated IST

    Participants with SAA/vSAA that are previously untreated with IST.

    Drug: Romiplostim · Drug: Antithymocyte Globulin · Drug: Cyclosporine A

  • Experimental
    Arm 2: Refractory IST

    Participants with SAA/vSAA that are refractory to IST.

    Drug: Romiplostim

Interventions

06

What researchers measure

Primary outcomes

  1. Arms 1 and 2: proportion of participants achieving any hematologic response at week 14

    Proportion of participants achieving any hematologic response at week 14 based on response criteria: * Platelet response * Erythroid response * Red blood cell count * Hemoglobin concentration * Neutrophil response

    Time frame: Week 14

Secondary outcomes

  1. Arm 1: number of participants who achieve a complete response (CR) or partial response (PR) at week 14

    Time frame: Week 14

  2. Arms 1 and 2: number of participants who have a decrease in frequency of platelet and/or red blood cell (RBC) transfusions, or become platelet and/or RBC transfusion independent at week 14

    Time frame: Week 14

  3. Arms 1 and 2: number of participants with serious adverse events

    Time frame: 24 Weeks

  4. Arms 1 and 2: number of participants with clinically significant changes in laboratory values

    Time frame: 24 Weeks

  5. Arms 1 and 2: change from baseline in Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) bleeding scale at week 14

    The Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto is as follows: 0: No bleeding 1. Petecjoae or mucosal or retinal bleeding that did not require red-cell transfusion 2. Melena, hematemesis, hematuria, or hemoptysis 3. Any bleeding that required red-cell transfusion 4. Retinal bleeding accompanied by visual impairment 5. Nonfatal cerebral bleeding 6. Fatal cerebral bleeding 7. Fatal noncerebral bleeding

    Time frame: Baseline and Week 14

  6. Arms 1 and 2: serum romiplostim trough concentrations

    Time frame: Prior to romiplostim administration on Weeks 1, 2, 4, 5, 9, 13, and 24

  7. Arms 1 and 2: maximum serum concentration (Cmax) of romiplostim

    Time frame: Weeks 1, 2, 4, 5, 9, 13, and 24

  8. Arms 1 and 2: area under the curve (AUC) of romiplostim

    Time frame: Weeks 1, 2, 4, 5, 9, 13, and 24

  9. Arms 1 and 2: time to reach maximum concentration (tmax) of romiplostim

    Time frame: Weeks 1, 2, 4, 5, 9, 13, and 24

  10. Arms 1 and 2: half-life (t1/2) of romiplostim

    Time frame: Weeks 1, 2, 4, 5, 9, 13, and 24

  11. Arms 1 and 2: number of participant with anti-romiplostim antibodies

    Time frame: Prior to romiplostim administration on Weeks 1 and 13

  12. Arms 1 and 2: number of participants with antibodies to thrombopoietin

    Time frame: Prior to romiplostim administration on Weeks 1 and 13

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2023; primary completion for Feb 2025, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2022
First posted
Apr 12, 2022
StartEst.
Aug 31, 2023
Primary completionEst.
Feb 25, 2025
CompletionEst.
Feb 25, 2025
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05323617
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Aug 31, 2023 (estimated)
Primary completion
Feb 25, 2025 (estimated)
Completion
Feb 25, 2025 (estimated)
Last update
Sep 29, 2023

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion